LOXO ONCOL is a pharmaceutical company focused on Oncology, Metabolic, Neurology. Key products include JAYPIRCA.
FDA Novel Drug Designations
(2023)See 1 novel approval →
LOXO ONCOL at a Glance
- Fast trial execution (3 months median completion)
LOXO ONCOL's Key Drugs
LOXO ONCOL's core commercial portfolio centers on JAYPIRCA, spanning Oncology and Metabolic — its most strategically important drugs approved in the last 15 years.
LOXO ONCOL's Recent FDA Approvals
New NDA/BLA approvals for LOXO ONCOL over the last two years — novel drugs only, excluding generics and label supplements.
LOXO ONCOL's Therapeutic Areas
LOXO ONCOL's approved drugs and pipeline span 3 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
LOXO ONCOL's Top Competitors
LOXO ONCOL's closest competitors by therapeutic-area and drug-target overlap include Eli Lilly, Roche, and Pfizer. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
LOXO ONCOL Pipeline Snapshot
LOXO ONCOL has 10 active clinical programs from ClinicalTrials.gov — 7 Phase 3, 2 Phase 2 and 1 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • JAYPIRCA leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 0/6 completed
- • Speed: 3 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2023-01-27
- Latest
- 2025-12-02
- Applications
- 1
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges